Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2016  |  Volume : 12  |  Issue : 5  |  Page : 54-56

S-1 combined with cisplatin chemotherapy for advanced gastric cancer


Department of Clinical Pharmacy, Lishui People's Hospital of Zhejiang Province, Lishui 323000, PR China

Correspondence Address:
Xia Lijun
Department of Clinical Pharmacy, Lishui People's Hospital of Zhejiang Province, Lishui 323000
PR China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-1482.191631

Rights and Permissions

Objective: To observe the short-term efficacy and safety of S-1 combined with cisplatin (DDP) chemotherapy for advanced gastric cancer (AGC). Materials and Methods: Sixty-six patients were diagnosed with AGC and were admitted to our department from February 2012 to January 2015 and retrospectively analyzed. Of these patients, 31 (experimental group) underwent S-1 combined with DDP chemotherapy and 35 received oxaliplatin combined with tegafur and calcium folinate chemotherapy regimen (control group). The chemotherapy regimen for the experimental group included S-1, 60 mg bid on d1–d14 and 60 mg/m 2 DDP by intravenous dripping on d1–d3, with 4 weeks in a cycle. The chemotherapy regimen for the control group consisted of 130 mg/m 2 oxaliplatin by intravenous dripping, d1; 600 mg/m 2 tegafur by intravenous dripping on d1–d5; and 120 mg/m 2 calcium folinate by intravenous dripping on d1–d5, with 3 weeks in a cycle. The efficacies and adverse effects of the two regimens were assessed after three cycles. Results: After three cycles, the objective response rates of the experimental and control groups were 41.94% and 42.86%, without significantly difference (P > 0.05), respectively. However, the incidence rate of adverse drug reactions in Grades 3–4 in the experimental group was significantly lower than that of control group (P < 0.05). Conclusion: The short-term efficacy of primary S-1 with DDP chemotherapy for AGC is relatively satisfactory with less adverse effects.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1784    
    Printed25    
    Emailed0    
    PDF Downloaded100    
    Comments [Add]    

Recommend this journal